北京天智航医疗科技股份有限公司 关于 2025 年度"提质增效重回报"行动方案的半年度评估报告 北京天智航医疗科技股份有限公司（以下简称"公司"或"天智航"）为切 实践行"以投资者为本"的上市公司发展理念，维护公司全体股东特别是广大中 小投资者利益，基于对公司未来发展前景的信心、对公司价值的认可和切实履行 社会责任，于 2025 年 4 月 29 日发布《关于 2024 年度"提质增效重回报"行动 方案的年度评估报告暨 2025 年度"提质增效重回报"行动方案》，为公司 2025 年度提质增效重回报行动制定出明确的工作方向。公司根据行动方案内容，积极 开展和落实各项工作，现将 2025 年上半年行动方案主要举措的进展及成效情况 报告如下： 公司实现营业收入 12,531.24 万元，较上年同期增长 114.89%。2025 年 1 月至 6 月，天玑骨科手术机器人开展手术量超过 2.2 万例；截至报告期末，累计开展手 术量超过 12 万例。伴随着天玑骨科手术机器人的接受度和使用量的快速提升， 公司的可持续经营能力也将不断提升。 品向高性价比、高性能迭代升级，不断丰富产品种类和产品功能。目前，公司产 品适应证已 ...

Core Points - The annual general meeting of Beijing Tianzhihang Medical Technology Co., Ltd. is scheduled for May 20, 2025, at 10:00 AM, combining on-site and online voting methods [4][5][12] - The company reported a net profit of -121.13 million yuan for 2024, with no distributable profits available [10][11] - The company plans to issue shares to specific targets, with a total financing amount not exceeding 1 billion yuan [12][13] Meeting Procedures - Attendees must confirm their identity upon arrival, and the meeting will follow a predetermined agenda for discussion and voting [2][3] - Shareholders have the right to speak, inquire, and vote, but must adhere to time limits and order during discussions [2][3] - The meeting will be witnessed by a legal representative from a law firm, ensuring compliance with legal standards [3][4] Financial Performance - The company achieved a total revenue of 178.84 million yuan in 2024, with significant contributions from orthopedic surgical robots and related services [15][16] - The sales of consumables increased by 55.27% from 33.88 million yuan in 2023 to 52.60 million yuan in 2024 [15][16] - The company has conducted over 39,000 surgeries using its orthopedic surgical robots in 2024, with a cumulative total exceeding 100,000 surgeries by the end of the year [16][17] Product Development - The company expanded its product offerings, gaining approval for new applications of its orthopedic surgical robots, including total hip replacement surgeries [16][17] - The orthopedic surgical navigation system received CE certification, marking a significant step in the company's international expansion strategy [17] Governance and Oversight - The board of directors held 12 meetings in 2024, addressing major operational decisions and ensuring compliance with legal and regulatory requirements [19][20] - The supervisory board conducted 12 meetings, overseeing the company's operations and ensuring adherence to financial regulations [23][24] - The company emphasizes investor relations, maintaining open communication channels to enhance transparency and protect shareholder interests [21][22]